Press Releases

03.20.2026

Pfizer Recommends Shareholders Reject the Mini-Tender Offer by Tutanota LLC

03.19.2026

TALZENNA Plus XTANDI Significantly Improves Radiographic Progression-Free Survival in Metastatic Prostate Cancer

03.17.2026

Pfizer Announces Positive Topline Phase 2 Results for Next-Generation CDK4 Inhibitor, Atirmociclib, in Second-Line Metastatic Breast Cancer

03.09.2026

Pfizer’s Phase 2 Study of Trispecific Antibody Positive in Moderate to Severe Atopic Dermatitis

02.27.2026

PADCEV™ + Keytruda® Cuts Risk of Recurrence or Death by Nearly 50% in Cisplatin-Eligible Muscle-Invasive Bladder Cancer

02.24.2026

U.S. FDA Grants Full Approval to Pfizer’s BRAFTOVI Combination Regimen in First-Line Metastatic Colorectal Cancer

02.23.2026

Pfizer Invites Public to Listen to Webcast of Pfizer Discussion at Healthcare Conference

02.17.2026

Pfizer’s BRAFTOVI Regimen Improves Progression-Free Survival in Metastatic Colorectal Cancer

02.06.2026

FDA Grants Priority Review for HYMPAVZI® (marstacimab) sBLA for the Treatment of Two Hemophilia A or B Patient Populations with Significant Medical Need

02.05.2026

Pfizer Launches Cost Savings Program on TrumpRx Lowering Drug Costs for Millions of Americans

02.03.2026

Pfizer Reports Solid Full-Year 2025 Results And Reaffirms 2026 Guidance

02.03.2026

Pfizer’s Ultra-Long-Acting Injectable GLP-1 RA Shows Robust and Continued Weight Loss with Monthly Dosing in Phase 2b Trial